Ectonucleotide pyrophosphatase-phosphodiesterase-1 inhibitors and pharmaceutical compositions comprising the same

A compound represented by following Formula 1, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof:

• wherein,
• A1 is a substituted or unsubstituted C3-30 cycloalkyl ring, a substituted or unsubstituted C2-30 heterocycloalkyl ring, a substituted or unsubstituted C6-30 aryl ring, or a substituted or unsubstituted C3-30 heteroaryl ring, fused to an adjacent ring;
• A2 is a substituted or unsubstituted C3-20 cycloalkylene group, a substituted or unsubstituted C2-20 heterocycloalkylene group, a substituted or unsubstituted C6-30 arylene group, or a substituted or unsubstituted C3-30 heteroarylene group;
• X1 to X4 are each independently CR or N;
• R is hydrogen, a hydroxy group, a halogen group, a C1-10 alkyl group, a C1-10 alkoxy group, a C6-20 aryl group, a C3-20 heteroaryl group, a C3-10 cycloalkyl group, a C3-10 heterocycloalkyl group, an amino group, a nitro group, an amide group, a carboxyl acid group, a nitrile group, a urea group, or a sulfonamide group;
• L1 is a C1-10 alkylene group or a C2-10 alkenylene group;
• Z is represented by
• R1 is O or NR5;
• R2 is hydrogen, a hydroxy group, a cyano group, a C1-C10 alkyl group, a C1-10 alkoxy group, a C6-C12 aryl group, a C3-C10 cycloalkyl group, a C2-C12 heterocycloalkyl group, —C(═O)OR6, or —NR8R9;
• L21, L22 and L3 are each independently a single bond, a substituted or unsubstituted C1-C5 alkylene group, or —NR7—;
• R3 to R7 are each independently hydrogen or a C1-C5 alkyl group;
• R8 and R9 are each independently hydrogen, —C(═O)R10 (with the proviso that R10 is a C1-C5 alkyl group), or -Boc (tert-butoxycarbonyl);
• and
• * is a point connected to A2 in Formula 1.